Background: Muscle weakness is associated with increased mortality, and hemodialysis (HD) patients are at an increased risk for muscle loss. There is no agreed definition for muscle weakness, so we determined whether using different cut-off criteria recommended by guideline groups altered the prevalence in HD patients. Methods: We measured hand grip strength (HGS) in HD outpatients, comparing HGS with clinical guideline cut-offs (European Working Group on Sarcopenia in Older People [EWGSOP] and North American Foundation for the National Institutes of Health Sarcopenia Project [FNIH]) used to define muscle wasting (sarcopenia) with age-matched and gender-matched normative data. Results: We studied 459 patients, 61.4% male, 47.3% diabetic. The prevalence of muscle weakness was significantly different when measuring HGS; 84.5% using the EWGSOP cut-off and 73.2% with FNIH criteria, and 75.2% using North American normative data and 56.6% U.K. normative data (P < .01). On logistic regression, muscle weakness was associated with age (odds ratio [OR] 1.05, P < .001), weight (OR 0.96, P < .001), serum albumin (OR 0.89, P = .007), and being nondiabetic (OR 0.31, P = .001). Of patients with no comorbidity, 66.7% were weak when compared with 93.8% with the highest comorbidity scores (P < .001). Conclusion: There is currently no agreed universal definition for sarcopenia, but the EWGSOP and FNIH advocate HGS cut-offs as part of their definition. The prevalence of muscle weakness varies according to cut-off and whether age-matched and gender-matched normative data are used. In addition, patient characteristics in terms of age and comorbidity determine the prevalence of muscle weakness. (Nutr Clin Pract. 2018;33:255-260) 
In economically developed countries life expectancy continues to rise, with increasing numbers of elderly patients now treated by dialysis. Although muscle mass naturally declines after the age of 50, muscle wasting is associated with an increased risk for mortality. 1 Loss of lean body mass is often referred to as sarcopenia, a term derived from the Greek word for "loss of flesh." 2 Although there is no universally agreed consensus definition of sarcopenia, it is now defined by both European and North American interest groups by including a functional component. 3, 4 The measurement of hand grip strength (HGS) has been shown to be both a reproducible and reliable method of assessing forearm muscle strength and is established as an indicator of muscle status, particularly among older adults. 5 Several recent studies have reinforced the association between HGS with determinations of nutrition status, measurements of muscle mass, functional capacity, and overall health status. In the past few years, several studies have confirmed the value of grip strength as a significant predictor of patient mortality, length of hospital stay, and physical functioning. 6 Patients with chronic kidney disease treated by hemodialysis (HD) are at increased risk of losing muscle mass as a result of multiple factors, including dietary restrictions, metabolic acidosis, insulin resistance, 7 urinary and dialysate protein losses, and reduced physical activity along with fatigue and self-reported depression. 8, 9 Reports of studies using HGS measurements in HD patients have shown that HGS measurements are reliable and reproducible and not affected by the presence of an arterio-venous fistula or the dialysis session. [10] [11] [12] In addition, HGS weakness in HD patients is associated with increased mortality risk. 13 As there has been recent concordance in defining sarcopenia first by a loss of muscle strength measured by HGS by both the European Working Group on Sarcopenia in Older People (EWGSOP) 3 and the North American Foundation for the National Institutes of Health Sarcopenia Project (FNIH), 4 we determined the prevalence of muscle weakness using these definitions as well as comparing muscle weakness with age-matched and gender-matched controls.
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Methods
We retrospectively analyzed the results of HGS using the grip-D strength dynamometer (Takei Scientific Instruments Co., Nigata, Japan) in adult patients with chronic kidney disease attending outpatient HD under the care of a university hospital. Patients were instructed and shown how to use the strength gauge, and measurements were made according to the manufacturer's recommendations with patients asked to make their maximal voluntary exertion. Three measurements were made with the dominant arm, and the maximal value recorded.
Muscle weakness was defined according the EWGSOP and FNIH sarcopenia cut-off definitions (EWGSOP male, 32 kg and female, 22 kg; FNIH sarcopenia male, < 26 kg and female, < 16 kg), 3, 4 respectively, and > 2 standard deviations below age-matched and gender-matched normative adult values. 15, 17 When comparing clinical guideline cutoffs, as the dialysis population was from a European center, we chose the EWGSOP as the reference clinical guideline. We used the World Health Organization body mass index cut-offs (23.0, 27.5, 32.5, and 37.5 kg/m 2 ) to divide patients into 5 categories. 18 Patient demographics were obtained from hospital computerized healthcare records. Patient comorbidity was determined using the Davies-Stoke comorbidity scoring system, as this has been validated in a U.K. dialysis population. 19 Patients were dialyzed using polysulfone dialyzers (Nipro, Osaka, Japan), 20 Fresenius 4008H, 5008 (Fresenius AG, Bad Homberg, Germany), or BBraun Dialogue+ (BBraun, Melsungen, Germany) dialysis machines, and anticoagulated with tinzaparin, a lowmolecular-weight heparin (Leo Laboratories, Market Harborough, U.K.). 21 Serum biochemistry samples were analyzed with a standard multichannel biochemical analyzer (Roche Integra, Roche Diagnostics, Lewes, U.K.) using the bromocresol green method for albumin determination, and hemoglobin samples by the sodium lauryl sulphate-Hb method (XE-2100 Sysmex Corporation, Kobe, Japan), 22 and the dialysate biochemistry was checked. 23 Dialyzer clearance was calculated on sessional urea clearance (single pool Kt/Vurea) and that estimated by the dialysis machine (on-line Kt/V). Urea appearance rate was calculated as the difference in total body urea predialysis and postdialysis using total body water predialysis and postdialysis divided by the interdialytic period and then adjusted to a 70 kg patient. B2 microglobulin was measured using a nephelometric assay. 24 This retrospective audit complied with the U.K. National Health Service guidelines for clinical audit and service development (available at http://www.hra.nhs.uk/ documents/2013/09/defining-research.pdf and http://www. gov.uk/government/publications/health-research-ethicscommittees-governancearrangements). 
Statistical Analysis
Results
We retrospectively analyzed the results of body composition from 459 adult HD patients; 282 (61.4%) males, mean age 66.9 ± 15.0 years, 46.6% diabetic, with a median vintage HD treatment of 36.4 (15.2-72.4) months. The major ethnic groups were White 43.4%, South Asian 26.5%, AfricanAfro-Caribbean 20.3%, East Asian 5.6%, and other ethnic groups 4.2%. Mean HGS was 18.3 ± 9.5 kg. Depending on the cut-off criteria advised by different studies, more male patients had muscle weakness using the EWSOP cut-off values, and more female patients had muscle weakness using the EWSOP guidelines when compared with the FNIH sarcopenia project or Dodd and Bohannon normative values ( Figure 1) .
We then compared the prevalence of muscle wasting using the EWGSOP cut-off criteria with those of the FNIH sarcopenia project and Dodd and Bohannon normative values (Table 1) . There was poor agreement between muscle weakness according to the EWGSOP cut-off and those , and > 2 standard deviations from gender-matched and age-matched normative data, with 1st author name. *P < .05, **P < .01, ***P < .001 vs EWSOP.
from the FNIH sarcopenia project or Dodd and Bohannon normative values.
As expected, male patients had greater HGS than females, and older patients had weaker muscle strength (Table 2) . Patients with muscle weakness had lower weights, but body mass index was only lower in the male patients. Predialysis systolic blood pressure was similar between groups, although those patients with reduced HGS had lower predialysis diastolic blood pressures. Haemoglobin and C reactive protein were not different, although serum albumin and cholesterol levels were lower in those with muscle weakness. Dialysis vintage, in terms of months of dialysis treatment, and β2 microglobulin were not different, as was dialysis urea clearance (urea reduction ratio) and dialysis machine estimated and calculated sessional Dialyzer sessional urea clearance (Kt/Vurea).
Patients with muscle weakness had greater comorbidity scores, but apart from previous myocardial infarction, coronary artery stenting, and diabetes, other comorbidities, including peripheral vascular disease, stroke, transient ischemic attacks, cirrhosis, and malignancy, were not different (Table 3) . Using the EWSOP guidelines for defining sarcopenia, there were no differences between ethnic groups for women, although fewer African-Afro-Caribbean male patients had muscle weakness (Figure 2) . A logistic regression model for muscle weakness showed that older age, diabetic status, lower weight, and serum albumin level were all independently associated with muscle weakness (Table 4) , whereas gender was not a significant factor.
Discussion
Sarcopenia is associated with an increased risk of mortality.
1 To detect muscle loss at an early stage to allow for effective interventions, rapid, low-cost screening tests are required for every day clinical practice. Although relying on patient participation requiring a measurement of maximum voluntary muscle strength, HGS has been shown to be a reliable reproducible test to detect muscle weakness that can be readily performed in the clinic and on the dialysis unit. 13, 25 Previous reports have shown that HGS is a robust test of muscle strength that is not affected by patient self-reported distress. 12 Although there is no consensus definition for sarcopenia, speciality interest groups in both North America and Europe recommend measuring HGS in diagnosing sarcopenia. 3, 4 We measured HGS in a large, multiethnic dialysis population attending for outpatient dialysis treatments. Using the EWGSOP cut-off, muscle weakness was more commonly found in older patients with lower body weight. Overall comorbidity scores were greater in those patients with muscle weakness, and they were more likely to have a medical history of myocardial infarction or coronary artery stenting, which may account for the lower diastolic blood pressure. In addition, patients with diabetes mellitus were more likely to have muscle weakness, and other studies have reported that diabetic dialysis patients have greater body fat and less muscle mass than nondiabetics. 26 Previous reports have suggested differences in body composition between different ethnic groups, 27 and we noted a lower prevalence of muscle weakness for male patients of AfricanAfro-Caribbean descent. There was no difference in dialysis vintage or β2 microglobulin, a marker of residual renal function, 27 between groups of patients divided by gender β2M, β2 microglobulin; BMI, body mass index; Chol, cholesterol; CRP, C reactive protein; DBP, diastolic blood pressure; Gluc, glucose; Hb, haemoglobin; HGS, hand grip strength; nUAR, urea appearance rate mmol/day adjusted to 70 kg; OL-Kt/Vurea, online Kt/Vurea; Pi, serum phosphate; SBP, predialysis systolic blood pressure; spKt/Vurea, single pool Kt/V; URR, urea reduction ratio. *P < .5, **P < .01, ***P < .001 vs no weakness cohort. those who were weaker had lower serum urea, serum albumin level, cholesterol level, and urea generation rate, whereas only serum albumin level and cholesterol level were significantly lower in the weaker female patients. This would suggest that these patients probably had lower nutrition intakes, and previous studies have reported an association between muscle weakness and malnourishment in dialysis patients, 28 although lower urea generation could also be associated with less physical activity, 29 another cause of muscle wasting. 7 In addition, the lower serum albumin level could be consistent with an inflammatory state, although C reactive protein concentrations did not differ. Previous reports have described a syndrome of muscle wasting and inflammation in dialysis patients. 30 Comparing the EWGSOP cut-off with that recommended by the FNIH sarcopenia project group, the prevalence of muscle wasting was greater using the EWGSOP guidelines. 3, 4 In addition, we also used age-matched and gender-matched normative data. The prevalence of muscle weakness was lower using U.K. and North American agematched and gender-matched normative data for males, but there was no difference between the EWGSOP and North American age-matched data, whereas the prevalence of muscle weakness was much lower using U.K. agematched normative data. 5, 13 Because neither the EWG-SOP and FNIH sarcopenia cut-offs are age adjusted, one would expect that they would overestimate muscle weakness when comparing muscle strength with age-adjusted normative data. The difference between genders may have been a result of the slightly lower age of our female patients.
As muscle strength decreases with age, 5,13 on multivariable analysis using the EWGSOP cut-off then older age was the strongest factor associated with muscle weakness, followed by lower weight. Patients with diabetes mellitus and lower serum albumin level were also independently associated with muscle weakness.
There is currently no single, agreed consensus definition for muscle wasting to differentiate muscle wasting that is associated with the normal aging process from pathological muscle loss, and our study highlights the differences between the current guidelines. Similarly, it remains to be established whether the criteria for muscle loss should be disease specific. Although patients with chronic conditions are generally less physically active, some diseases are more likely to be associated with joint and metabolic bone disease and so may have additional effects on reducing muscle strength as assessed by HGS.
Taking different cut-offs leads to differences in reported prevalence of muscle wasting, potentially leading to overreporting and conversely underreporting between studies. 29, 31 In addition, differences in patient demographics will also have an effect on reported prevalence. Because we performed a cross-sectional assessment, we do not have outcome data to determine an association between muscle weakness and mortality risk. Whether muscle weakness is a primary risk factor for mortality 32 remains to be determined as muscle weakness is also associated with increasing comorbidity and lower serum albumin level.
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